Matrix stiffening related lncRNA SNHG8 regulates chemosensitivity of ovarian cancer.
10.7507/1001-5515.202205038
- Author:
Zina CHENG
1
;
Xiaolu MA
1
;
Quanyou ZHANG
1
;
Weiyi CHEN
1
Author Information
1. College of Biomedical Engineering, Taiyuan University of Technology, Taiyuan 030024, P. R. China.
- Publication Type:Journal Article
- Keywords:
Chemosensitivity;
Long non-coding RNA;
Matrix stiffness;
Ovarian cancer;
SNHG8
- MeSH:
Female;
Humans;
Cisplatin/pharmacology*;
Elasticity/physiology*;
Etoposide;
Extracellular Matrix/physiology*;
Ovarian Neoplasms/metabolism*;
RNA, Long Noncoding/metabolism*
- From:
Journal of Biomedical Engineering
2023;40(1):87-94
- CountryChina
- Language:Chinese
-
Abstract:
Extracellular matrix (ECM) has been implicated in tumor progress and chemosensitivity. Ovarian cancer brings a great threat to the health of women with a significant feature of high mortality and poor prognosis. However, the potential significance of matrix stiffness in the pattern of long non-coding RNAs (lncRNAs) expression and ovarian cancer drug sensitivity is still largely unkown. Here, based on RNA-seq data of ovarian cancer cell cultured on substrates with different stiffness, we found that a great amount of lncRNAs were upregulated in stiff group, whereas SNHG8 was significantly downregulated, which was further verified in ovarian cancer cells cultured on polydimethylsiloxane (PDMS) hydrogel. Knockdown of SNHG8 led to an impaired efficiency of homologous repair, and decreased cellular sensitivity to both etoposide and cisplatin. Meanwhile, the results of the GEPIA analysis indicated that the expression of SNHG8 was significantly decreased in ovarian cancer tissues, which was negatively correlated with the overall survival of patients with ovarian cancer. In conclusion, matrix stiffening related lncRNA SNHG8 is closely related to chemosensitivity and prognosis of ovarian cancer, which might be a novel molecular marker for chemotherapy drug instruction and prognosis prediction.
